816
Participants
Start Date
January 24, 2023
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2024
Descovy
Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
HQ Toronto, Toronto
Collaborators (1)
Gilead Sciences
INDUSTRY
HQ Toronto
OTHER